Method for rapid separation of liposome-associated doxorubicin from free doxorubicin in plasma

Thies, Robert L.; Cowens, D W; Cullis, Pieter R.; Bally, Marcel B.; Mayer, Lawrence D.

doi:10.1016/0003-2697(90)90528-h

Cited by 48 publications

(27 citation statements)

References 8 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Analytical methods for the measurement of released and liposomal drugs in plasma samples have previously been developed. These methods utilize ultracentrifugation [18], solid phase extraction (SPE) [19][20][21][22], gel filtration [19] and ultrafiltration in off-line sample preparation procedures [23]. However, most of these separation methods have limitations, which include difficulty in separating the large liposomes by ultracentrifugation, drug adsorption to ultrafiltration devices, high sample dilution during gel chromatography, and potential drug release from the liposomes during sample preparation using reversed phase SPE [24].…”

Section: Introductionmentioning

confidence: 99%

Direct, simultaneous measurement of liposome-encapsulated and released drugs in plasma by on-line SPE–SPE–HPLC

Yamamoto

Hyôdô

Ohnishi

et al. 2011

Journal of Chromatography B

View full text Add to dashboard Cite

Section: Introductionmentioning

confidence: 99%

Direct, simultaneous measurement of liposome-encapsulated and released drugs in plasma by on-line SPE–SPE–HPLC

Yamamoto

Hyôdô

Ohnishi

et al. 2011

Journal of Chromatography B

View full text Add to dashboard Cite

“…Analytical methods for the measurement of released and encapsulated drugs in plasma samples have previously been reported. However, these methods need complex sample preparation procedures, such as ultracentrifugation, 16) solid phase extraction (SPE), [17][18][19][20] gel filtration 17) or ultrafiltration 21) before analysis. These separation methods have a potential risk of sample deterioration: adsorption to ultrafiltration devices, high sample dilution during gel chromatography, and drug release from the liposomes during reversed phase SPE.…”

Section: Development Of Analytical Methods To Ensure the Quality Of Dmentioning

confidence: 99%

Development of Liposomal Anticancer Drugs

Hyôdô

Yamamoto

Suzuki

et al. 2013

Biological & Pharmaceutical Bulletin

View full text Add to dashboard Cite

Liposomes are drug delivery systems that can alter the pharmacokinetic properties of compounds. The adverse effects of anticancer agents are a limiting factor for cancer chemotherapy, therefore, liposomal formulations have the potential to improve the therapeutic efficacy of anticancer agents by enhancing their accumulation in tumors and reducing non-selective distribution to normal tissues, which is known as the enhanced permeability and retention effect. To develop a liposomal anticancer agent as a drug product, its formulation must be designed to ensure its quality until it is administered to patients and to exert maximum potency in clinical use rather than in animal experiments. The chemical stability and physicochemical stability of the ingredients are key factors in the design of liposomal formulations. Drug release rates are critical factors in the therapeutic efficacy of liposomal drug products because the encapsulated drug has no pharmacological activity, and only released drug can exert antitumor/toxic activities. Liposomes should maintain the drug in a stable state in the circulation and then promptly release it after accumulation in the target tissue in order to achieve a sufficient drug concentration. To understand the profile of the formulation and to guarantee the quality of drug product, a reliable analytical method that can determine the released and encapsulated drugs in biological fluids is required. Simple online solid phase extractions of the released and encapsulated drugs using a column-switching HPLC system meet the requirements and this system enables accurate in vitro release testing and in vivo pharmacokinetic evaluation. This review introduces the process of liposomal drug product development from various viewpoints.

show abstract

“…Validated assays to reliably determine free doxorubicin concentrations among relatively large quantities of liposome-associated doxorubicin are necessary and a number of such assays have been described. They use ion-exchange (Druckmann et al 1989), solid state extraction (Thies et al 1990;Griese et al 2002), and ultrafiltration (Mayer and St-Onge 1995). A capillary electrophoresis assay with separation of free doxorubicin and liposome associated doxorubicin in the capillary was recently described by Kim and Wainer 2010) (Also see Chap.…”

Section: Physicochemical Characterizationmentioning

confidence: 99%